Alkermes About
Alkermes: Alkermes®
is a world leader in the development of products based on sophisticated drug delivery
technologies-and an emerging pharmaceutical company. Alkermes
develops sustained-release injectable drugs using their ProLease® and Medisorb®
technologies, and inhaled formulations based on their proprietary AIR® pulmonary
technology. In
partnership with Johnson & Johnson, Alkermes is marketing Risperdal® Consta™,
a long-acting newer-generation antipsychotic for the treatment of schizophrenia.
Developed with Medisorb® technology, Pipeline: Alkermes' lead product candidate, Vivitrex (naltrexone), is a once-a-month
injection for the treatment of alcohol dependence. Pipeline
Chart
Phase III Vivitrex Alchol
Dependence
Phase
II Medisorb Diabetes
Phase II AIR
Insulin Diabetes
Phase I AIR
hGH GHD
Phase I AIR
Epinephrine Anaphylaxis
More on Alkermes: